Lenvatinib Induces AKT/NF-κB Inactivation, Apoptosis Signal Transduction and Growth Inhibition of Non-small Cell Lung...

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Non-small cell lung cancer (NSCLC) presents a significant clinical challenge due to its poor prognosis.
• Lenvatinib, a multi-kinase inhibitor, has shown potential in preclinical studies for cancer therapy.
• Previous in vitro research indicated lenvatinib induces apoptosis in CL-1-5-F4 cells.

Purpose of the Study:

• To investigate the in vivo efficacy of lenvatinib in suppressing NSCLC progression.
• To evaluate the impact of lenvatinib on tumor growth and relevant molecular pathways in a preclinical NSCLC model.
• To assess the normal tissue toxicity of lenvatinib in vivo.

Main Methods:

• Tumor growth inhibition was assessed in CL-1-5-F4-bearing mice treated with lenvatinib.
• Bioluminescence imaging and caliper measurements were used to quantify tumor growth.
• Western blot analysis was employed to evaluate the phosphorylation status of AKT and NF-κB signaling pathways in tumor tissues.
• Histopathological examination was conducted on major organs (liver, kidney, spleen) to assess toxicity.

Main Results:

• Lenvatinib treatment significantly reduced tumor growth, as evidenced by decreased tumor volume and bioluminescence intensity.
• The drug effectively suppressed the phosphorylation of AKT and NF-κB signaling pathways, crucial for tumor progression.
• No significant pathological changes or toxicity were observed in the liver, kidney, or spleen following lenvatinib administration.

Conclusions:

• Lenvatinib demonstrates in vivo efficacy in inhibiting NSCLC progression through the induction of apoptosis.
• Suppression of the AKT/NF-κB signaling pathway is a key mechanism underlying lenvatinib's anti-tumor activity in NSCLC.
• Lenvatinib exhibits a favorable safety profile with no observed toxicity in normal tissues in this preclinical study.